Female Contraception Market Size, Share, Analysis, Forecast, Industry Strategy, Opportunity, Trends, Insights, Growth, Price, Research Survey, Segment, Outlook and Challenges Report To 2016
Female Contraception Market Size, Share, Analysis, Forecast, Industry Strategy, Opportunity, Trends, Insights, Growth, Price, Research Survey, Segment, Outlook and Challenges Report To 2016
Market Reports Center latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception Pipeline Review, H2 2016, provides an overview of the Female Contraception( Women ' s Health) pipeline landscape.
Contraception( birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices( IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg( barrier and IUD methods), preventing an egg from being released every month( hormones), blocking the reproductive function( sterilization) and preventing a fertilized egg from implanting in the uterus( hormones).
Report Highlights
Market Reports Center Pharmaceutical and Healthcare latest pipeline guide Female Contraception – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Contraception( Women ' s Health), complete with analysis by stage of development, drug target, mechanism of action( MoA), route of administration( RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
To Get Complete Report: https:// marketreportscenter. com / reports / 490761 / femalecontraception-pipeline-review-h2-2016
The Female Contraception( Women ' s Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.